Nature Biotechnology

Germany caps drug prices

Nature Biotechnology 28, 539 (2010). doi:10.1038/nbt0610-539c

Author: Suzanne Elvidge

Biotech breeding goes bovine

Nature Biotechnology 28, 540 (2010). doi:10.1038/nbt0610-540

Author: Stephen Strauss

Dairy farmers are rapidly adopting molecular profiling to accelerate the process of siring cows. But this seismic shift in breeding practices is raising new questions and translating more slowly to the beef industry. Stephen Strauss reports.

Up for grabs

Nature Biotechnology 28, 544 (2010). doi:10.1038/nbt0610-544

Author: Michael Eisenstein

As issued patents on induced pluripotent stem (iPS) cells stack up, the specter of a patent thicket looms. Michael Eisenstein investigates.

1 out of 27—European politicians score poorly in agbiotech

Nature Biotechnology 28, 551 (2010). doi:10.1038/nbt0610-551

Authors: Atanas Atanassov, Godelieve Gheysen, Denis J Murphy, Olivier Sanvido, Joachim Schiemann, Charles Spillane & Roberto Tuberosa

Split approvals and hot potatoes

Nature Biotechnology 28, 552 (2010). doi:10.1038/nbt0610-552

Author: Henry I Miller

Why drought tolerance is not the new Bt

Nature Biotechnology 28, 553 (2010). doi:10.1038/nbt0610-553

Authors: Travis J Lybbert & Adrian Bell

Health impact in China of folate-biofortified rice

Nature Biotechnology 28, 554 (2010). doi:10.1038/nbt0610-554

Authors: Hans De Steur, Xavier Gellynck, Sergei Storozhenko, Ge Liqun, Willy Lambert, Dominique Van Der Straeten & Jacques Viaene

Alive and kicking

Nature Biotechnology 28, 556 (2010). doi:10.1038/nbt0610-556

Author: Lance Stewart

Pluripotent patents make prime time: an analysis of the emerging landscape

Nature Biotechnology 28, 557 (2010). doi:10.1038/nbt0610-557

Authors: Brenda M Simon, Charles E Murdoch & Christopher T Scott

An examination of three patents in the fast-moving iPS space may help determine their ultimate value.

Recent patent applications in epigenetics

Nature Biotechnology 28, 560 (2010). doi:10.1038/nbt0610-560

Raising the bar for cancer therapy models

Nature Biotechnology 28, 561 (2010). doi:10.1038/nbt0610-561

Authors: Giulio Francia & Robert S Kerbel

Can mouse cancer models predict the results of phase 3 clinical trials?

Scalable pluripotent stem cell culture

Nature Biotechnology 28, 562 (2010). doi:10.1038/nbt0610-562

Author: Larry A Couture

Large-scale production of human embryonic stem cells will require improved culture methods.

Complex molecular dynamics in the spotlight

Nature Biotechnology 28, 564 (2010). doi:10.1038/nbt0610-564

Authors: Lois Pollack & Watt W Webb

Zero-mode waveguides illuminate the process of translation.

Detecting methylated bases in real time

Nature Biotechnology 28, 565 (2010). doi:10.1038/nbt0610-565

Author: Markus Elsner

Research highlights

Nature Biotechnology 28, 566 (2010). doi:10.1038/nbt0610-566

Erratum: The cancer vaccine roller coaster

Nature Biotechnology 28, 624 (2010). doi:10.1038/nbt0610-624a

Author: Bruce Goldman & Laura DeFrancesco

Erratum: Irish bioethics council axed

Nature Biotechnology 28, 624 (2010). doi:10.1038/nbt0610-624b

Author: Cormac Sheridan

Erratum: Never again

Nature Biotechnology 28, 624 (2010). doi:10.1038/nbt0610-624c

Author: Chris Scott

Erratum: Resuscitated deCODE refocuses on diagnostics

Nature Biotechnology 28, 624 (2010). doi:10.1038/nbt0610-624d

Author: Mark Ratner

Erratum: Biotech in a blink

Nature Biotechnology 28, 624 (2010). doi:10.1038/nbt0610-624e

Author: Ken Garber